Status:
COMPLETED
15-day Sequential Therapy for Helicobacter Pylori Infection in Korea
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
Ministry of Education, Republic of Korea (2012R1A1A3A04002680)
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
10-day sequential therapy was not sufficient to overcome tough situation for H. pylori eradication in Korea due to high antimicrobial resistance. The present investigators assumed that doubling durati...
Eligibility Criteria
Inclusion
- patients with H. pylori infection who had never received treatment for H. pylori infection
- H. pylori infection defined by a positive rapid urease test (CLOtest, Delta West, Bentley, Australia) by gastric mucosal biopsy from the lesser curvature of the mid antrum or mid body or histological evidence of H. pylori by modified Giemsa staining in the lesser and greater curvature of the mid antrum or mid body, respectively or a positive C-urea breath test.
Exclusion
- Patients with concurrent critical illness, a history of previous upper gastrointestinal surgery, contraindication to any of the study medications, recent frequent intake of NSAIDs, anticoagulants or steroids, an allergy to the study medications, and those that were pregnant or breast-feeding women were excluded from the study. Other exclusion criteria include recent use of antimicrobials and any condition probably associated with poor compliance such as drug abusers or alcoholics.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT01887249
Start Date
May 1 2010
End Date
July 1 2013
Last Update
August 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Bundang-gu, Seongnam, Gyeonggi-do, South Korea, 463-707